Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, making up about 85% of all cases. Among the genetic mutations associated with NSCLC, the ALK (anaplastic lymphoma kinase) EML4 (echinoderm microtubule-associated protein-like 4) fusion gene is one of the significant biomarkers for targeted therapy. Identifying the presence of this genetic alteration […]











